(Q43939236)

English

Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma

scientific article published in April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

28 November 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Ying Chen

1

1 reference

Europe PubMed Central

28 November 2017

Brian I Rini

2

1 reference

Europe PubMed Central

28 November 2017

Angel H Bair

3

1 reference

Europe PubMed Central

28 November 2017

Ganesh M Mugundu

4

1 reference

Europe PubMed Central

28 November 2017

Yazdi K Pithavala

5

1 reference

Europe PubMed Central

28 November 2017

publication date

1 April 2015

1 reference

Europe PubMed Central

28 November 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

28 November 2017

54

1 reference

Europe PubMed Central

28 November 2017

4

1 reference

Europe PubMed Central

28 November 2017

397-407

1 reference

Europe PubMed Central

28 November 2017

https://scigraph.springernature.com/pub.10.1007/s40262-014-0207-5

0 references

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

VEGF kinase inhibitors: how do they cause hypertension?

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Chemotherapy agents and hypertension: a focus on angiogenesis blockade

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Ambulatory blood-pressure monitoring

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Clinical pharmacology of axitinib

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Bayesian methods for pharmacokinetic/pharmacodynamic modeling of pazopanib-induced increases in blood pressure and transaminases.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0207-5

21 January 2018

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25343945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/25343945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25343945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements

1 reference

https://pubmed.ncbi.nlm.nih.gov/25343945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variability of indirect methods used to determine blood pressure. Office vs mean 24-hour automated blood pressures.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25343945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertension as a predictive factor of Sunitinib activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25343945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-014-0207-5

1 reference

Europe PubMed Central

28 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43939236&oldid=2144162450"